Several studies have found some prognostic-related biomarkers such as CD8 (+) T lymphocytes (Zhang et al., 2019; Lin J et al., 2020) and tumor-infiltrating CD19 (+) B lymphocytes (Lin et al., 2018); however, a single biomarker is not enough to identify the efficacy of immunotherapy accurately. This evidence concerns the gene CD8A and neoplasm.